Compare Heron Therapeutics Inc (HRTX) vs MobilEye Global Inc (MBLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs MobilEye Global Inc — how do they compare? Heron Therapeutics Inc trades at $0.35 (market cap $61.47M), while MobilEye Global Inc trades at $8.76 (market cap $7.54B). The key difference: MobilEye Global Inc is far larger — about 122.7× Heron Therapeutics Inc's market cap, and MobilEye Global Inc is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| HRTX | MBLY | |
|---|---|---|
Market Cap | $61.47M | $7.54B |
Sector | Health | Technology |
52-Week High | $1.49 | $15.54 |
52-Week Low | $0.32 | $6.56 |
Enterprise Value | $168.21M | $6.10B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.3152, down 4.54% today, amid bearish technical signals and mixed earnings. The stock shows a high gross margin of 70.07% but negative net income margins, with Q2 2026 missing revenue and EPS estimates. Recent news highlights patent litigation developments and quarterly results falling short of expectations, contributing to investor caution.
The outlook remains challenged by persistent losses and operational cash burn, though analyst consensus is strongly bullish with 94.74% buy ratings. Key risks include execution on product sales, competitive pressures, and reliance on financing activities to sustain operations amid negative profitability.
Mobileye Global Inc. (MBLY) trades at $8.81, up 0.69% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong Q2 2026 earnings beats, driven by an R&D grant, though it remains unprofitable with a net income margin of -201.49%. Recent news highlights CEO transition plans and a new supply deal with Stellantis, while analyst consensus is bullish with a $11.40 price target.
The outlook is mixed: raised 2026 guidance and strategic partnerships offer growth potential in autonomous driving, but persistent losses, leadership changes, and high valuation multiples pose significant risks. Investors should weigh the company's technological positioning against its current financial health and execution challenges in a competitive market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About MobilEye Global Inc
Mobileye Global Inc. is a global leader in the development and deployment of Advanced Driver Assistance Systems (ADAS) and autonomous driving technologies. The company specializes in computer vision, machine learning, and data analysis to create sensing, mapping, and driving policy solutions. Mobileye's technology, including its EyeQ system-on-chips and its crowd-sourced mapping platform (REM), is integrated into vehicles worldwide, aiming to improve road safety and enable the future of autonomous mobility.
Read more on MBLY →
